Covestro Ag Stock Earnings Reports

Key points for investors: Covestro completed the Pontacol purchase in Q3 2025 and has signed another value-accretive deal to acquire two HDI-derivative facilities from Vencorex (Rayong, Thailand and Freeport, U.S.) to expand aliphatics capacity in the U.S. and APAC; expected to add a low double-digit million euro to EBITDA plus synergies up to high double-digit million euros within five years. Q3 sales fell 12% to EUR 3.2bn (volumes -1.5%) driven by negative pricing, FX headwinds and the Dormagen fire incident; Q3 EBITDA was EUR 242m (toward the top of the guided range) supported by cost savings and an insurance reimbursement. Covestro estimates the Dormagen outage will burden FY‑2025 EBITDA by up to ~EUR 150m; partial TDI production has resumed with a gradual ramp through 2026 dependent on chlorine availability. Insurance heads-up: a EUR 75m internal insurance payment was received and management expects coverage above an initial ~EUR 100m threshold (deductible ~EUR 25m). Free operating cash flow was positive EUR 111m in Q3 but 9M FCF remains negative (‑EUR 370m); CapEx guidance remains EUR 700–800m. FY 2025 guidance narrowed: EBITDA EUR 700–800m (midpoint EUR 750m), FCF between EUR ‑400m and ‑200m, sales now ~EUR 13.0bn. Management cites persistent market oversupply and a negative pricing delta versus raw materials as the main margin headwinds, partly offset by accelerated cost and transformation actions (including potential pulling forward of restructuring costs). Net debt-to-EBITDA sits at ~3.8x; Moody’s confirmed an investment-grade rating with stable outlook. The XRG transaction is progressing and management expects to close by the December 2 long-stop date, but German FDI and EU FSR approvals remain outstanding.